Chieh-Ju Lee
Overview
Explore the profile of Chieh-Ju Lee including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
151
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mon H, Lee P, Hung Y, Hung Y, Wu C, Lee C, et al.
J Hepatol
. 2024 Jul;
82(1):51-61.
PMID: 39084471
Background & Aims: Immune checkpoint inhibitors (ICIs) can restore exhausted T-cell immunity not only for cancer treatment but also potentially to cure chronic hepatitis B (CHB). Thus, we aimed to...
2.
Lim M, Muquith M, Miramontes B, Lee C, Espinoza M, Huang Y, et al.
Hepatology
. 2023 May;
78(6):1755-1762.
PMID: 37254559
Background And Aims: Immunotherapies have altered the treatment paradigm in HCC. Surrogate and modified endpoints are used to assess early success in clinical studies and guide clinical practice. We sought...
3.
Patterns and outcomes of subsequent therapy after immune checkpoint inhibitor discontinuation in HCC
Sharma R, Pillai A, Marron T, Fessas P, Saeed A, Jun T, et al.
Hepatol Commun
. 2022 Apr;
6(7):1776-1785.
PMID: 35481940
The availability of immune checkpoint inhibitors (ICIs) for the management of advanced hepatocellular cancer (HCC) has changed the treatment paradigm. There are emerging questions regarding the efficacy of subsequent anticancer...
4.
Wu C, Lee P, Hung Y, Lee C, Chi C, Lee I, et al.
Cancer Immunol Immunother
. 2022 Mar;
71(11):2631-2643.
PMID: 35347395
Background: Lenvatinib combined with pembrolizumab showed a promising result in an early phase study for hepatocellular carcinoma (HCC). The efficacy and safety of lenvatinib plus pembrolizumab for patients with unresectable...
5.
Jun T, Ozbek U, Dharmapuri S, Hardy-Abeloos C, Zhu H, Lin J, et al.
Ther Adv Med Oncol
. 2021 May;
13:17588359211010937.
PMID: 33995594
Background: Antibiotic exposure has been associated with worse outcomes with immune checkpoint inhibitors (ICIs) in cancer patients, likely due to disruption of the gut microbiome. Other commonly prescribed medications, such...
6.
Chen K, Huang Y, Teo W, Chang C, Chen Y, Yeh Y, et al.
Cancers (Basel)
. 2021 Jan;
13(1).
PMID: 33406664
Tid1, a mitochondrial co-chaperone protein, acts as a tumor suppressor in various cancer types. However, the role of Tid1 in hepatocellular carcinoma (HCC) remains unclear. First, we found that a...
7.
Pinato D, Kaneko T, Saeed A, Pressiani T, Kaseb A, Wang Y, et al.
Cancers (Basel)
. 2020 Jul;
12(7).
PMID: 32664319
Immune checkpoint inhibitors (ICI) have shown positive results in patients with hepatocellular carcinoma (HCC). As liver function contributes to prognosis, its precise assessment is necessary for the safe prescribing and...
8.
Lee P, Chao Y, Chen M, Lan K, Lee C, Lee I, et al.
Cancers (Basel)
. 2020 Jan;
12(1).
PMID: 31940757
Immune checkpoint inhibitors (ICIs) with nivolumab and pembrolizumab are promising agents for advanced hepatocellular carcinoma (HCC) but lack of effective biomarkers. We aimed to investigate the potential predictors of response...
9.
Lee I, Yang S, Lee C, Su C, Wang Y, Lan K, et al.
J Infect Dis
. 2018 May;
218(7):1075-1084.
PMID: 29741704
Background: The long-term incidence and factors associated with hepatitis B surface antigen (HBsAg) loss in hepatitis B e antigen (HBeAg)-negative chronic hepatitis B (CHB) patients receiving peginterferon is rarely reported....